<DOC>
	<DOC>NCT02318602</DOC>
	<brief_summary>This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric and adult subjects with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled over from previous trials: INS011-14-029 (NCT02324673), INS011-14-024 (NCT02318537), or INS011- 14-025 (NCT02318563).</brief_summary>
	<brief_title>Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Completed all scheduled visits in the treatment phase of their core study Informed consent/assent (as applicable) was voluntarily provided by the participant and/or parent(s)/caregiver(s) in accordance with applicable laws, regulations, and local requirements Is medically stable with no anticipated changes in chronic medications Continues to meet protocolspecified criteria for qualification and contraception, including treatmentresistant seizure disorder In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to continue keeping accurate seizure diaries Inadequate supervision by parent(s)/caregiver(s) History or current use of dietary supplements, drugs or overthe counter medications outside protocolspecified parameters Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding) 3. the analysis of results</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lennox-Gastaut syndrome</keyword>
	<keyword>Dravet syndrome</keyword>
	<keyword>Treatment-resistant seizures</keyword>
</DOC>